Ardelyx now sees 2026 IBSRELA revenue between $350 mln and $370 mln
Company reiterates 2026 XPHOZAH revenue guidance of $110 mln to $120 mln
Ardelyx expects 2026 operating expenses below $500 mln
Overview
U.S. biopharma firm's Q2 product revenue rose 31% yr/yr to record $118.1 mln
IBSRELA Q2 revenue grew 33% but was below company expectations due to payor restrictions
Company reported Q2 net loss of $16.7 mln, narrowing from prior year
Result Drivers
Demand for IBSRELA - Co said Q2 growth was driven by increased refills and total prescriptions, reaching highest demand quarter to date
Payor restrictions - Co said IBSRELA Q2 revenue was below expectations due to significantly increased utilization management processes from payors
Demand for XPHOZAH - Co said Q2 growth was driven by strong increase in total writers, new and refill prescriptions, and total prescriptions
Analyst coverage and valuation
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
ARDX•
